Therefore, targeting the ER and HER2 receptors simultaneously is likely to be a fruitful approach for the treatment of HR+/HER2+ (triple positive) breast cancer, and the occurrence of side effects may decrease significantly in this combination application. This evidence concerns the gene ERBB2 and breast carcinoma.